Loading candles…
Divis Laboratories Ltd, incorporated in 1990, operates in the pharmaceutical industry as a manufacturer and exporter of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. The company’s operations are primarily divided into two business segments: Generic APIs and Custom Synthesis of APIs and intermediates for global innovator pharmaceutical companies. Divis Laboratories serves global export markets and is recognized as one of the top three global API manufacturers. It partners with 20 of the world’s leading pharmaceutical innovators. The company emphasizes backward integration and supply chain reliability, leveraging its expertise in chemistry and large-scale manufacturing processes. There are no subsidiaries or listed exchanges associated with the company in the provided facts.
This page is a live market overview for DIVI S LABORATORIES LTD (DIVISLAB) on the NSE. As a listed security, DIVI S LABORATORIES LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for DIVISLAB before placing trades on tick2trade.
As of the latest feed, DIVISLAB last traded at ₹8,275 on NSE, down ₹74 (0.89%) from the previous close of ₹8,349. Today's session range is ₹8,233.5 – ₹8,334, against a 52-week band of ₹5,636.5 – ₹8,585. Traded volume today stands at 2.57L shares.
The overview consolidates an interactive price chart with multiple time ranges, a near-the-money option chain snapshot, recent market headlines, upcoming corporate events for DIVISLAB in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether DIVISLAB is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for DIVI S LABORATORIES LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in DIVISLAB. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated DIVISLAB option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 and dividend | 23 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 11 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 7 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 6 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 17 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.